More than 5 years ago, a New York Times article
described stunning effects of angiogenesis inhibitors in eradicating cancerous
tumors in mice, unleashing a media frenzy. But the agents have failed to perform
as hoped in the clinic. More than 60 antiangiogenic agents are in clinical
trials in the United States, and while they appear to be safe and well tolerated,
positive therapeutic outcomes have been scarce .
Hampton T. Cancer Researchers Target Angiogenesis. JAMA. 2003;290(19):2529–2533. doi:10.1001/jama.290.19.2529
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: